US FDA approves Amgen and Allergan's Avastin biosimilar

By Gareth Macdonald contact

- Last updated on GMT

iStock/MarianVejcik
iStock/MarianVejcik

Related tags: Food and drug administration, Monoclonal antibodies

US regulators have approved Amgen Inc’s Mvasi (bevacizumab-awwb), a biosimilar version of Roche’s monoclonal antibody (mAb) cancer treatment Avastin (bevacizumab). 

The decision​, which is in line with a recommendation made by the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) in July​, clears Mvasi for the treatment of the same cancers as Avastin.

The approval states that the mAb is a biosimilar but not interchangeable with the Roche drug.

Amgen developed Mvasi in collaboration with Allergan under a deal signed in 2010. The agreement covered the development of four cancer biosimilars.

An Amgen spokeswoman told us "In the collaboration with Allergan, Amgen has primary responsibility for the development, manufacture and initial commercialization of the products; whereas Allergan will provide funding over the course of development as well as expertise gained in the commercialization and marketing of products​."

She declined to comment when asked when Mvasi would be launched in the US or if it would be sold at a discounted rate relative to the innovator drug.

"The FDA’s approval is an exciting step towards recognizing Mvasi as an important treatment option for certain patients with cancer. The patent information exchange under the regulatory scheme governing biosimilars (the BPCIA) is ongoing. We have not commented on launch timelines​."

In December​, Amgen announced that it Mvasi – previously known as ABP 215 – submitted for review by the European Medicines Agency (EMA).

Related news

Show more

Related products

show more

Infographic - road map to commercialization

Infographic - road map to commercialization

MilliporeSigma - Gene Therapy | 19-Oct-2020 | Infographic

With the current increase in development and investment, gene therapy companies will increasingly be looking to streamline the manufacture and commercialization...

Process Development for Viral Vector Manufacturing

Process Development for Viral Vector Manufacturing

MilliporeSigma - Gene Therapy | 15-Oct-2020 | Infographic

Process development is a crucial step in viral vector manufacturing and a successful CDMO partnership can help navigate the challenges associated with...

Related suppliers

Follow us

Products

View more

Webinars